Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE011 (ITA) (Dr. Jansen)
· consented 2023-07-15
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-10-03 (study day 65); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Constipation — outcome: UNKNOWN; onset 2024-01-28 (study day 182); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-12 (study day 197); relationship: N
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2024-02-19 (study day 204); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-11 (study day 225); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-12-10 (study day 499); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.